Use your own digital technology to count the NCI scientists and tumor tissue of small RNA molecules for identifying melanoma treatment of seven potential immune therapy target. Immunotherapy works by that increase the body's immune system or by using immune cells to attack the cancer cells of a particular type. Overexpression of the success of this treatment for melanoma and cancers of all forms, or very active, is contingent upon finding a protein target cancerous tumor cells have limited expression in normal tissues. 7 That is identified in this work meets the requirements of these gene target. The results of this study led by NCI Division of Cancer Research Center for tumor immunology, surgery branch Morgan Dr. Richard a. 9/10/2013, appeared in clinical cancer research.
Designed a genetic probe containing 97 Morgan and his colleagues looking for a target on the new treatment for malignant melanoma, 72, was considered immune therapy for potential candidate genes and gene sets. Genetic probes for each permit individual RNA molecules accurately count NCI research team, a unique fluorescent barcode had. 59 By using probe isolated researcher in melanoma tumor samples and genetic material RNA to protein, the code sets, and counted each time the barcode gene have been observed. The results of this experiment, scientists concluded 33 of 72 potential target genes overexpression of more than 20% of the malignant melanoma tumor samples. 20 And is expressed in normal tissue samples of tumors of those genes, different methods were identified. Based on this analysis, the researchers conclusions 7 gene warrant potential as a target for immunotherapy of further consideration: found high expression in a large percentage of CSAG2, MAGEA3, MAGEC2 and IL13RA2, PRAME, CSPG4, and SOX10, tumor samples that had limited expression in normal tissues.
No comments:
Post a Comment